Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Cloud-Based Rare Disease Family Registry Market Expansion From $1.64 Billion In 2026 To $3.14 Billion In 2030

The market for cloud-based rare disease family registries has experienced substantial expansion recently, with a projected increase from $1.4 billion in 2025 to $1.65 billion in 2026, reflecting a compound annual growth rate of 17.7%. This upward trajectory during the historical period is largely attributable to the proliferation of rare disease research endeavors, heightened engagement from patient advocacy groups, the broadening of clinical trial infrastructures, greater utilization of electronic data capture technologies, and the fundamental requirement for unified systems to manage patient information.

The market for cloud-based rare disease family registries is projected for significant expansion in the coming years, anticipating an increase to $3.15 billion by 2030, fueled by a compound annual growth rate (CAGR) of 17.5%. This projected increase during the forecast period is largely a consequence of heightened investments directed towards the development of orphan drugs, a surge in the need for real-world evidence, the broadening scope of precision medicine research, the increasing application of AI in data analysis, and a greater emphasis on research models centered around the patient. Key developments anticipated within this timeframe include a greater uptake of cloud-based patient registries, expanded utilization of digital platforms for rare disease research endeavors, enhanced integration between genomic and clinical data sets, improvements in global clinical trial recruitment instruments, and a more pronounced focus on safeguarding data through secure sharing practices.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28178&type=smp

Cloud-Based Rare Disease Family Registry Market Demand Drivers: What Is Fueling Industry Growth?

The expansion of the cloud-based rare disease family registry market is anticipated to be driven by the growing emphasis on precision medicine. This approach to healthcare involves customizing treatment and preventative measures based on an individual’s genetic predispositions, surrounding environmental influences, and personal lifestyle choices. Advances in genomic sequencing technology have significantly contributed to the rise of precision medicine, enabling healthcare professionals to gain a more precise understanding of a patient’s genetic composition. Cloud-based registries for rare diseases play a crucial role in facilitating precision medicine by gathering and consolidating comprehensive patient data, encompassing genetic profiles, clinical histories, and therapeutic interventions. A compelling illustration of this trend emerged in February 2024 when the Personalized Medicine Coalition, a nonprofit entity based in the United States, announced that the U.S. Food and Drug Administration (FDA) had approved 16 novel personalized therapies for individuals suffering from rare diseases during 2023, a substantial increase from the six approvals recorded in 2022; among these newly sanctioned treatments, seven were specifically developed for cancer indications, while three addressed other ailments and conditions. Consequently, the escalating adoption of precision medicine is a key factor spurring the growth within the market for cloud-based rare disease family registries.

Cloud-Based Rare Disease Family Registry Market Categorization By Product Type And Application

The cloud-based rare disease family registry market covered in this report is segmented –

1) By Component: Software, Services

2) By Deployment Mode: Public Cloud, Private Cloud, Hybrid Cloud

3) By Application: Patient Data Management, Research, Clinical Trials, Genetic Data Collection, Other Applications

4) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Patient Advocacy Groups, Other End-Users

Subsegments:

1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System

2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades

Cloud-Based Rare Disease Family Registry Market Innovation Trends: Which Developments Are Transforming The Industry?

Leading entities within the cloud-based rare disease family registry sector are actively pursuing technological advancements, including the implementation of bilingual federated registries, aiming to furnish patients, families, and researchers with robust, geographically dispersed data environments that foster greater engagement and facilitate immediate data gathering and examination. Such a bilingual federated registry represents a cloud-hosted architecture enabling data localization while accommodating diverse linguistic needs and adherence to local privacy mandates and consent protocols. By way of example, the National Organization for Rare Disorders (NORD), a non-profit organization based in the United States, had scheduled for June 2025 the introduction of two patient registries in Canada, specifically for PKU and MPS. These registries, conceived in partnership with Canadian patient advocacy organizations, researchers, and medical professionals, mark the inaugural instances within the IAMRARE Program to be situated beyond the U.S. Their design prioritizes compliance with provincial consent stipulations, empowers collaborative, real-time data acquisition and analysis, and aims to expedite research initiatives, deepen insights into rare metabolic conditions, and streamline the identification of suitable candidates for clinical studies.

Cloud-Based Rare Disease Family Registry Market Company Landscape And Strategic Competition

Major companies operating in the cloud-based rare disease family registry market are Thermo Fisher Scientific Inc., IQVIA Holdings Inc., ICON plc, Syneos Health Inc., Parexel International Corp., Medidata Solutions Inc., FIGMD Inc., OM1 Inc., Mission Health Labs Inc., TREAT-NMD Global Registries Platform, Seqster PDM Inc., ArborMetrix Inc., OpenClinica LLC, Pulse Infoframe Inc., Oracle Healthcare Pvt. Ltd., QuesGen Systems Inc., FTD Disorders Registry, Castor LLC, Data Registry Services LLC, Fibrolamellar Registry, Rare Central

Access The Complete Cloud-Based Rare Disease Family Registry Market Report:

https://www.thebusinessresearchcompany.com/report/cloud-based-rare-disease-family-registry-global-market-report

Cloud-Based Rare Disease Family Registry Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the cloud-based rare disease family registry market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cloud-based rare disease family registry market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model